Rehovot, Israel Sept. 13th 2010 -- D-Pharm Ltd., (DPRM: TASE) a technology-driven biopharmaceutical company focused on the discovery and development of innovative proprietary drugs for the treatment of central nervous system disorders, announced today that it has been shortlisted for a 2010 Scrip Award.
This nomination recognizes the major achievements D-Pharm has made in the last 12 months. These include commencement of the MACSI Phase III study with DP-b99 in acute ischemic stroke patients under IND and SPA; the company’s successful listing on the Tel Aviv stock exchange; and licensing of the marketing rights for DP-b99 in China. Four other companies were nominated by a judging panel of 19 industry experts in the category, “Best Company in An Emerging Market”.
The Scrip Awards is a major event for the biotechnology and pharmaceutical industry, with the awards being highly contested. The event is in its 6th year and the awards ceremony will take place on 4th November, 2010 in London. http://www.scripintelligence.com/awards/
About D-Pharm Ltd.
D-Pharm (www.dpharm.com) is a leader in design and development of lipid-like medicine and its products are new chemical entities (NCEs) derived from its proprietary platform technology. The drug development pipeline includes two products in advanced stages of clinical development: DP-b99 (phase 3) for treatment of acute ischemic stroke patients and DP-VPA (phase 2) for treatment of epilepsy, bipolar disorder and prophylaxis of migraine; and preclinical drug-candidates for Alzheimer’s disease and cancer.
Contact: Email: Tami Horovitz thorovitz@dpharm.com
